Ultragenyx Pharmaceutical Inc.
RARE
$29.78
$0.260.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.77% | 33.46% | 29.01% | 27.44% | 19.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.77% | 33.46% | 29.01% | 27.44% | 19.47% |
| Cost of Revenue | 6.44% | 6.78% | 8.81% | 96.38% | 35.54% |
| Gross Profit | 10.75% | 12.92% | 6.05% | -314.39% | -52.95% |
| SG&A Expenses | 8.62% | 6.40% | 3.81% | 3.31% | 3.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.26% | 7.94% | 9.24% | 5.53% | -4.23% |
| Operating Income | 7.97% | 11.52% | 5.84% | 9.62% | 18.42% |
| Income Before Tax | 9.62% | 11.07% | 6.72% | 11.62% | 17.88% |
| Income Tax Expenses | 246.12% | 231.47% | 187.51% | -589.67% | -128.68% |
| Earnings from Continuing Operations | 8.92% | 10.40% | 6.17% | 12.01% | 18.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.92% | 10.40% | 6.17% | 12.01% | 18.82% |
| EBIT | 7.97% | 11.52% | 5.84% | 9.62% | 18.42% |
| EBITDA | 8.94% | 13.24% | 7.87% | 12.10% | 20.96% |
| EPS Basic | 24.17% | 26.72% | 23.93% | 28.01% | 28.85% |
| Normalized Basic EPS | 24.92% | 28.41% | 24.47% | 27.39% | 28.03% |
| EPS Diluted | 24.17% | 26.72% | 23.93% | 28.01% | 28.85% |
| Normalized Diluted EPS | 24.92% | 28.41% | 24.47% | 27.39% | 28.03% |
| Average Basic Shares Outstanding | 19.24% | 21.46% | 23.12% | 22.75% | 14.98% |
| Average Diluted Shares Outstanding | 19.24% | 21.46% | 23.12% | 22.75% | 14.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |